TEVA-TERBINAFINE TABLET
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
21-10-2014
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE)
Available from:
TEVA CANADA LIMITED
ATC code:
D01BA02
INN (International Name):
TERBINAFINE
Dosage:
125MG
Pharmaceutical form:
TABLET
Composition:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 125MG
Administration route:
ORAL
Units in package:
100
Prescription type:
Prescription
Therapeutic area:
ALLYLAMINES
Product summary:
Active ingredient group (AIG) number: 0132855001; AHFS:
Authorization status:
CANCELLED PRE MARKET
Authorization date:
2015-10-16
Summary of Product characteristics
_TEVA-TERBINAFINE _
_ Page 1 of 44_
PRODUCT MONOGRAPH
PR
TEVA-TERBINAFINE
(terbinafine hydrochloride)
125 mg and 250 mg tablet
(expressed as base)
Teva Standard
ANTIFUNGAL AGENT
Teva Canada Limited
Date of Revision:
30 Novopharm Court
October 7, 2014
Toronto, Canada
M1B 2K9
www.tevacanada.com
Control No.: 177227
_TEVA-TERBINAFINE _
_ Page 2 of 44_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT INFORMATION
...........................................................................................................3
INDICATIONS AND CLINICAL USE
................................................................................................................3
CONTRAINDICATIONS
......................................................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................................................4
ADVERSE REACTIONS
......................................................................................................................................8
DRUG INTERACTIONS
.....................................................................................................................................11
DOSING CONSIDERATIONS
...........................................................................................................................15
OVERDOSAGE
...................................................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
...............................................................................................16
STORAGE AND STABILITY
............................................................................................................................17
SPECIAL HANDLING INSTRUCTION
.................................................................
Read the complete document
